牛牛AI助手已提取核心信息荣昌生物2025年第三季度营业收入达17.2亿元人民币，同比增长42.27%，主要受益于注射用泰它西普和注射用维迪西妥单抗销量增加。期内净亏损5.51亿元，亏损幅度较去年同期显著收窄，每股基本亏损1.01元。研发投入方面，前三季度研发支出为8.91亿元，同比下降22.79%，研发投入占营收比例降至51.78%。研发支出下降主要由于公司优化研发管线，且与美国Vor Bio...
Source Link牛牛AI助手已提取核心信息荣昌生物2025年第三季度营业收入达17.2亿元人民币，同比增长42.27%，主要受益于注射用泰它西普和注射用维迪西妥单抗销量增加。期内净亏损5.51亿元，亏损幅度较去年同期显著收窄，每股基本亏损1.01元。研发投入方面，前三季度研发支出为8.91亿元，同比下降22.79%，研发投入占营收比例降至51.78%。研发支出下降主要由于公司优化研发管线，且与美国Vor Bio...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.